Combined intervention of <i>Akkermansia muciniphila</i> and sodium butyrate ameliorates oxaliplatin-induced peripheral neuropathy by suppressing neuroinflammation and reducing serum neurofilament light chain.

Front Immunol · 2026 · PMC12995751 · PMID 41859089

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP = 0.0805so close (0.05 < p ≤ 0.1)

a positive trendno p-value reported

Furthermore, a correlation analysis indicated a positive trend between fecal acetate and butyrate levels (r = 0.3562), although this did not reach statistical significance ( P = 0.0805, Figure 8D ). 4 Discussion OIPN remains a critical dose-limiting side effect in diverse chemotherapy regimens, with currently limited therapeutic options ( 6 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Combined intervention of &lt;i&gt;Akkermansia muciniphila&lt;/i&gt; and sodium butyrate ameliorates oxaliplatin-induced peripheral neuropathy by suppressing neuroinflammation and reducing serum neurofilament light chain.

The sentences

Combined intervention of <i>Akkermansia muciniphila</i> and sodium butyrate ameliorates oxaliplatin-induced peripheral neuropathy by suppressing neuroinflammation and reducing serum neurofilament light chain.